Intravitreal triamcinolone acetonide and intraocular pressure

Am J Ophthalmol. 2004 Nov;138(5):740-3. doi: 10.1016/j.ajo.2004.06.067.


Purpose: To analyze the incidence of intraocular pressure (IOP) elevation following intravitreal triamcinolone injection.

Design: Retrospective observational case series.

Methods: Charts of patients undergoing intravitreal triamcinolone injection in one clinical practice were reviewed. A pressure elevation was defined as a pressure of 24 mm Hg or higher during follow-up.

Results: There were 89 patients with a mean age of 76.4 years. The mean baseline IOP was 14.9 mm Hg with a mean change of 8.0 mm Hg. Thirty-six patients (40.4%) experienced a pressure elevation to 24 mm Hg or higher at a mean of 100.6 days (SD = 83.1 day) after treatment. Of nonglaucomatous patients with baseline IOP of 15 mm Hg or above, 60.0% experienced a pressure elevation, compared with only 22.7% of those with baseline pressures below 15 mm Hg (relative risk = 2.1, P < .01). In glaucoma patients, 6 of 12 (50%) experienced a pressure elevation, and this elevation was not correlated with baseline pressure. Thirty-two patients (36.0%) received repeat injections, and there was no difference in the incidence of procedure elevation in patients receiving multiple injections versus those receiving a single injection. Pressure elevation was controlled with topical medications in all patients.

Conclusions: IOP elevation after intravitreal triamcinolone injection is common and may take an extended period of time to manifest. The proportion of patients who developed a pressure elevation to at least 24 mm Hg was much higher for those with baseline IOP 15 mm Hg or greater.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • Humans
  • Incidence
  • Injections
  • Intraocular Pressure / drug effects*
  • Male
  • Middle Aged
  • Ocular Hypertension / chemically induced*
  • Retinal Diseases / drug therapy
  • Retrospective Studies
  • Risk Factors
  • Triamcinolone Acetonide / administration & dosage
  • Triamcinolone Acetonide / adverse effects*
  • Vitreous Body


  • Glucocorticoids
  • Triamcinolone Acetonide